Chalcogen Bonded Directly To Ring Carbon Of The Hetero Ring Patents (Class 549/62)
-
Patent number: 9642886Abstract: The invention relates to a plant based formulation for the prevention and management of metabolic syndrome by its adiponectin enhancing property comprising of an effective amount of hydro-methanolic extract of Salacia reticulata, Tribulus terrestris, Curcuma longa and Dioscorea bulbifera and optionally additives in trace amounts.Type: GrantFiled: August 25, 2014Date of Patent: May 9, 2017Assignee: SRM UNIVERSITYInventors: Govind P. Dubey, Murugesan Ponnavaikko, Aruna Agarwal, Nirupama Dubey, Shipra Dubey
-
Patent number: 9328085Abstract: An expansion agent for hematopoietic stem cells and/or hematopoietic progenitor cells useful for improvement in the efficiency of gene transfer into hematopoietic stem cells for gene therapy useful for treatment of various disorders is provided. An expansion agent for hematopoietic stem cells and/or hematopoietic progenitor cells is provided, containing a compound represented by the formula (I): (wherein X, Y, Z, Ar1 , R1, R2, R3, R4, R5, R6 and R7 are as defined in the description), a tautomer, amide, ester, or pharmaceutically acceptable salt of the compound or a solvate thereof, which can expand hematopoietic stem cells and/or hematopoietic progenitor cells.Type: GrantFiled: May 2, 2013Date of Patent: May 3, 2016Assignee: Nissan Chemical Industries, Ltd.Inventors: Taito Nishino, Shunsuke Iwamoto, Katsuaki Miyaji
-
Publication number: 20150024267Abstract: The present invention relates to an electrolyte having improved high-rate charge and discharge property, and a capacitor comprising the same, and more particularly to an electrolyte having improved high-rate charge and discharge property comprising an aromatic compound, which comprises at least one compound of the following Chemical Formula 1 to Chemical Formula 11 that can induce resonance effect of electron movement, and which is a substituted organic compound in which a functional group is present at a location that can structurally prevent local polarization effect, and the boiling point of which is 80° C. or higher, wherein R in the Chemical Formula 1 to Chemical Formula 11 is at least one functional group selected from the alkyl group consisting of methyl, ethyl, propyl and butyl, and a capacitor comprising the same.Type: ApplicationFiled: September 30, 2014Publication date: January 22, 2015Inventor: Cheol Soo JUNG
-
Patent number: 8937148Abstract: Methods for producing regioregular poly(aryl ethynyl)-poly(aryl vinyl) and monomers for preparing the regioregular poly(aryl ethynyl)-poly(aryl vinyl) polymers are described herein. Regioregular poly(aryl ethynyl)-poly(aryl vinyl) are useful for electronics, among other things.Type: GrantFiled: September 7, 2012Date of Patent: January 20, 2015Assignee: Empire Technology Development LLPInventor: Glen Leon Brizius
-
Publication number: 20140349176Abstract: In an aspect, a rechargeable lithium battery that includes a positive electrode; negative electrode; a separator interposed between the positive electrode and the negative electrode; and an electrolyte including a lithium salt, a non-aqueous organic solvent, and an additive is provided. The additive may be an optionally substituted thiophene.Type: ApplicationFiled: April 22, 2014Publication date: November 27, 2014Applicant: Samsung SDI Co., Ltd.Inventors: Vladimir Egorov, Jiten Singh, Woo-Cheol Shin, Maeng-Eun Lee, Jung-Yi Yu, Sang-Il Han, Sang-Hoon Kim, Duck-Hyun Kim, Myung-Hwan Jeong, Seung-Tae Lee, Tae-Hyun Bae, Mi-Hyun Lee, Eon-Mi Lee, Ha-Rim Lee, Moon-Sung Kim, In-Haeng Cho, E-Rang Cho, Dong-Myung Choi, Makhmut Khasanov, Pavel Alexandrovich Shatunov, Alexey Tereshchenko, Denis Chernyshov
-
Patent number: 8889732Abstract: Fused heterocyclic compounds useful for prevention, treatment or improvement of diseases against which activation of the thrombopoietin receptor is effective are provided. A compound represented by the formula (I) (wherein R1 is an aryl group fused to a saturated ring or the like, A, B, L1, R2, L2, L3, Y, L4, R3 and X are defined in the description), a tautomer, prodrug or a pharmaceutically acceptable salt of the compound or a solvate thereof.Type: GrantFiled: October 22, 2010Date of Patent: November 18, 2014Assignee: Nissan Chemical Industries, Ltd.Inventors: Yukihiro Shigeta, Shingo Umezawa, Shunsuke Iwamoto, Takanori Nakamura
-
Publication number: 20140113941Abstract: This invention provides a compound having the structure wherein R1 is H, wherein n and q are independently an integer from 0 to 8; A is absent or present and when present is wherein m is an integer from 0 to 8; R3 is an amino, alkyl, aryl, heteroaryl, diol, piperazine, morpholine, piperidine, triazole, azide or biphenyl, each with or without substitution, branched or unbranched, or and R4 is alkyl, aryl, or heteroaryl, each with or without substitution, branched or unbranched, R2 is H, CH3, or alkyl, aryl, heteroaryl, pyrrole, diazole, or triazole, each with or without substitution, branched or unbranched, or wherein n and q are independently an integer from 0 to 8; A is absent or present and when present is and R6 is azide, methoxy, trifluoromethyl, biphenyl, substituted phenyl, substituted triazole, or alkyl, aryl or heteroaryl, with or without substitution, branched or unbranched, when R1 is H then R2 is other than H or CH3, andType: ApplicationFiled: March 23, 2012Publication date: April 24, 2014Applicant: The Research Foundation for The State University of New YorkInventors: Peter Tonge, Carl Machutta, Gopal Reddy Bommineni, Kanishk Kapilashrami
-
Patent number: 8680139Abstract: Disclosed are novel compounds which are useful as therapeutics, especially in anti-neoplastic therapy and in other therapeutic regimes where cysteine protease inhibition is implicated.Type: GrantFiled: March 31, 2010Date of Patent: March 25, 2014Assignee: ProgenraInventors: Ping Cao, Joseph Weinstock, William D. Kingsbury, Craig A. Leach, Suresh Kumar Kizhakkethil-George, Benjamin Nicholson
-
Patent number: 8563779Abstract: A description is given of (4-trifluoromethyl-3-thiobenzoyl)cyclohexanediones of the formula (I) and of their use as herbicides. In this formula (I), X, R1, R2, R3, and R4 are radicals such as hydrogen and organic radicals such as alkyl. A and Z are oxygen or alkylene.Type: GrantFiled: July 19, 2011Date of Patent: October 22, 2013Assignee: Bayer CropScience AGInventors: Hartmut Ahrens, Andreas Van Almsick, Elmar Gatzweiler, Dieter Feucht, Isolde Haeuser-Hahn, Stefan Lehr, Christopher Hugh Rosinger
-
Patent number: 8487120Abstract: Processes are provided for producing 3-(methylthio)thiophene by (i) combining at least an alkyl lithium, one or more alkanes and an ether to form a first combination, (ii) at a temperature of about ?30° C. to about ?25° C. and over a time period of at least about 30 minutes, adding 3-bromothiophene diluted in an ether to the first combination to form a second combination, (iii) at a temperature of about ?25° C. to about ?20° C. combining at least the second combination and dimethyl disulfide, and (iv) yielding at least the 3-(methylthio)thiophene.Type: GrantFiled: September 16, 2010Date of Patent: July 16, 2013Assignee: Albemarle CorporationInventors: Thierry Giard, Vincent L. Mutterer, Christophe Durvaux
-
Patent number: 8389202Abstract: A polymer includes a repeating unit shown by a general formula (1). R1 represents a hydrogen atom, a methyl group, a fluorine atom, or a trifluoromethyl group. R2 represents a substituted or unsubstituted aryl group having 6 to 22 carbon atoms. Y represents a carbon atom. X represents —X1Z1X2— which is an atomic group which forms a cyclic structure including a heteroatom together with Y. Z1 represents —O—, —S—, —CO—, —COO—, —SO—, or —SO2—. Each of X1 and X2 individually represents a single bond, a methylene group, or an alkylene group having 2 to 25 carbon atoms. Each of X1 and X2 is unsubstituted or substituted with a substituent, and optionally a carbon atom included in X1 and a carbon atom included in X2 are bonded via a divalent group.Type: GrantFiled: March 22, 2012Date of Patent: March 5, 2013Assignee: JSR CorporationInventors: Ken Maruyama, Toru Kimura
-
Patent number: 8389565Abstract: Methods for synthesizing Salacinol, its stereoisomers, and analogues, homologues and other derivatives thereof potentially useful as glycosidase inhibitors. In some embodiments the compounds of the invention may have the general formula (I) or (II): The synthetic schemes may comprise reacting a cyclic sulfate with a 5-membered ring sugar containing a heteroatom (X). The heteroatom preferably comprises sulfur, selenium, or nitrogen. The cyclic sulfate and ring sugar reagents may be readily prepared from carbohydrate precursors, such as D-glucose, L-glucose, D-xylose and L-xylose. The target compounds are prepared by opening of the cyclic sulfates by nucleophilic attack of the heteroatoms on the 5-membered ring sugars. The resulting heterocyclic compounds have a stable, inner salt structure comprising a heteroatom cation and a sulfate anion. The synthetic schemes yield various stereoisomers of the target compounds.Type: GrantFiled: March 2, 2006Date of Patent: March 5, 2013Assignee: Simon Fraser UniversityInventors: Brian Mario Pinto, Blair D. Johnston, Ahmad Ghavami, Monica Gabriela Szczepina, Hui Liu, Kashinath Sadalapure, Henrik H. Jensen, Nag Sharwan Kumar, Ravindranath Nasi
-
Patent number: 8318796Abstract: A compound represented by the formula (1): wherein A is a nitrogen atom or CR4, B is an oxygen atom, a sulfur atom or NR9 (provided that when A is a nitrogen atom, B is not NH), R1 is a C2-14 aryl group, L1 is a bond, CR10R11, an oxygen atom, a sulfur atom or NR12, X is OR13, SR13 or NR14NR15, R2 is a hydrogen atom, a formyl group, a C1-10 alkyl group or the like, L2 is a bond or the like, L3 is a bond, CR17R18, an oxygen atom, a sulfur atom or NR19, L4 is a bond, CR20R21, an oxygen atom, a sulfur atom or NR22, Y is an oxygen atom, a sulfur atom or NR23, and R3 is a C2-14 aryl group, a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.Type: GrantFiled: June 26, 2009Date of Patent: November 27, 2012Assignee: Nissan Chemical Industries, Ltd.Inventors: Shingo Owada, Shunsuke Iwamoto, Kazufumi Yanagihara, Katsuaki Miyaji, Takanori Nakamura, Norihisa Ishiwata, Yutaka Hirokawa
-
Publication number: 20120292577Abstract: Disclosed is a polythiophenes having high electrical conductivity, excellent solubility, long-term stability, excellent processability and high regioregularity. Specifically disclosed is regioregular polythiophene represented by chemical formula (1) wherein R1— represents a 4-substituent including an alkyl having 1 to 20 carbon atoms; R2—O— represents a 3-substituent including an alkyl having 1 to 20 carbon atoms; and n represents such a numeral value that the number average molecular weight of the regioregular polythiophene becomes 200 to 1,000,000, wherein the regioregularity of the Head-Tail repeating structure is at least 98%.Type: ApplicationFiled: January 18, 2011Publication date: November 22, 2012Applicant: KURARAY CO., LTD.Inventors: Taisuke Kamada, Shinji Nakai
-
Publication number: 20120178943Abstract: Processes are provided for producing 3-(methylthio) thiophene by (i) combining at least an alkyl lithium, one or more alkanes and an ether to form a first combination, (ii) at a temperature of about ?30° C. to about ?25° C. and over a time period of at least about 30 minutes, adding 3-bromothiophene diluted in an ether to the first combination to form a second combination, (iii) at a temperature of about ?25° C. to about ?20° C. combining at least the second combination and dimethyl disulfide, and (iv) yielding at least the 3-(methylthio) thiophene.Type: ApplicationFiled: September 16, 2010Publication date: July 12, 2012Applicant: Albemarle CorporationInventors: Thierry Giard, Vincent L. Mutterer, Christophe Durvaux
-
Patent number: 8067643Abstract: Compounds of the formula (I), L, L?, L?, L1, L?1, L?1, L2, L?2, L?2, L3, L?3, L?3, L4, L?4, L?4, L5, L?5, L?5, L6, L?6, L?6, L7, L?7, L?7, L8, L?8 and L?8 independently of one another are hydrogen or an organic substituent; and/or one or more of the pairs L3 and L5, L?3 and L?5 or L?3 and L?5 together denote a single bond, provided that the respective X, X? or X? is not a single bond; and/or L3 and L5, L?3 and L?5 or L?3 and L?5 together denote an organic linking group; and/or one or more of the pairs L1 and L3, L1 and L, L5 and L7, L?1 and L?3, L?1 and L?, L?5 and L?7, L?1 and L?3, L?1 and L?, or L?5 and L?7, together denote an organic linking group; provided that at least one of L, L?, L?, L1, L?1, L?1, L2, L?2, L?2, L3, L?3, L?3, L4, L?4, L?4, L5, L?5, L?5, L6, L?6, L?6, L7, L?7, L?7, L8, L?8 and L?8 is other than hydrogen; X, X? and X? independently of one another are a single bond, CRaRb O, S, NRc or NCORc; Ra, Rb and Rc independently of one another are hydrogen or an organic substituent; and Y is an inoType: GrantFiled: April 4, 2007Date of Patent: November 29, 2011Assignee: BASF SEInventors: Pascal Hayoz, Stephan Ilg
-
Patent number: 8048832Abstract: Fuels, especially hydrocarbon fuels, and lubricants, especially lubricating oils, contain a class of anti-corrosion, anti-wear, anti-fatigue, and extreme pressure additives that are derived from 1,3-dithiolane-2-thiones.Type: GrantFiled: March 24, 2009Date of Patent: November 1, 2011Assignee: Chemtura CorporationInventor: Robert G. Rowland
-
Patent number: 8039496Abstract: Disclosed herein is a compound of the formula. Therapeutic methods, compositions, and medicaments for the treatment of glaucoma or ocular hypertension related thereto are also disclosed.Type: GrantFiled: January 22, 2008Date of Patent: October 18, 2011Assignee: Allergan, Inc.Inventors: David W. Old, Vinh X. Ngo
-
Publication number: 20110250254Abstract: An agent comprising the compound according to general formula (I) wherein R1, R2, R3 and R4 are each independently H or a substituent, and wherein at least one of R1, R3 and R4 is halogen, cyano, cyanate, thiocyanate or C1-C6 haloalkyl.Type: ApplicationFiled: October 9, 2009Publication date: October 13, 2011Inventors: Anne Aamdal Scheie, Tore Benneche, Jessica Lonn-Stensrud, Jan Skramstad
-
Patent number: 8030327Abstract: The present invention relates to a compound represented by the Formula [I]: Wherein: the A ring is a 5-membered aromatic heterocyclic group containing at least one hetero atom selected from a nitrogen atom, and the like; A1 and A2, are each a nitrogen atom, and the like; X2, X3, X4, and X5 are all carbon atoms, or alternatively any one of X2, X3, X4, and X5 is a nitrogen atom and the rest are all carbon atoms; R1 is a hydrogen atom, or the like; R2, R3, R4, and R5, are each a hydrogen atom, or the like; R6 and R6?, are each a hydrogen atom, and the like; R7 is an aryl group and the like; and R8 is an amino group or a hydroxy group, or a pharmaceutically acceptable salt or ester thereof.Type: GrantFiled: November 7, 2005Date of Patent: October 4, 2011Assignee: MDS K.K.Inventors: Yoshiyuki Sato, Hideki Kurihara, Kaori Kamijo, Yu Onozaki, Toshiaki Tsujino, Tetsuya Sugimoto, Akiko Watanabe, Morihiro Mitsuya, Hideya Komatani
-
Patent number: 7999121Abstract: The present invention relates to methods of making derivatized 3,4-alkylenedioxythiophene monomers and methods of using the 3,4-alkylenedioxythiophene monomers.Type: GrantFiled: October 13, 2010Date of Patent: August 16, 2011Assignee: E. I. du Pont de Nemours and CompanyInventors: Shawn Yeisley, Charles J. Dubois, Che-Hsiung Hsu, Steven W. Shuey, Yulong Shen, Hjalti Skulason
-
Patent number: 7973180Abstract: The present invention provides a method for the production of an aqueous dispersion containing an electroconductive polymer component which enables electroconductive thin films which are outstanding in their transparency and electroconductivity to be formed, together with the aqueous dispersion obtained by said method. This method includes a stage in which a 3,4-dialkoxythiophene is polymerized in an aqueous solvent using an oxidizing agent in the presence of a polyanion and, in this stage, said oxidizing agent is added by the dropwise addition of a solution or dispersion containing said oxidizing agent to the reaction solution or, alternatively, in the polymerization stage, the alkali metal ion concentration in the reaction liquid is maintained at no more than 400 ppm.Type: GrantFiled: October 6, 2006Date of Patent: July 5, 2011Assignee: H.C. Starck GmbHInventors: Yoshiyuki Morita, Yasuo Chikusa, Kyoko Miyanishi, Stephan Kirchmeyer, Wilfried Loevenich
-
Patent number: 7943787Abstract: The subject invention pertains to pentafluorosulfonyl (SF5) substituted pyrroles, thiophenes, 3-pyrrolines and 2,5-dihydrothiophenes, as well as methods for their synthesis.Type: GrantFiled: June 17, 2010Date of Patent: May 17, 2011Assignee: University of Florida Research Foundation, Inc.Inventors: Zhaoyun Zheng, William R. Dolbier, Jr.
-
Publication number: 20110077406Abstract: Embodiments of the invention provide methods and materials for chemical cross-coupling reactions that utilize unconventional phenol derivatives as cross-coupling partners. Embodiments of the invention can be used to synthesize a variety of useful organic compounds, for example the anti-inflammatory drug flurbiprofen.Type: ApplicationFiled: September 24, 2010Publication date: March 31, 2011Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Neil K. Garg, Kyle W. Quasdorf, Xia Tian
-
Publication number: 20110040103Abstract: The subject invention pertains to pentafluorosulfonyl (SF5) substituted pyrroles, thiophenes, 3-pyrrolines and 2,5-dihydrothiophenes, as well as methods for their synthesis.Type: ApplicationFiled: June 17, 2010Publication date: February 17, 2011Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.Inventors: Zhaoyun Zheng, William R. Dolbier, JR.
-
Patent number: 7879979Abstract: The present invention relates to novel arginine analogs, and methods for their synthesis and use. Such analogs are designed to provide a protected or free thiol (—SH) group, thereby providing a convenient linkage chemistry for coupling to a suitable group on a target such as a protein, polypeptide, detectable label or solid phase, and at a site distal to the guanidino group. Arginine analog conjugates are useful for generating antibodies that can bind specifically with dimethylarginine, which can be detected using such antibodies in immunoassays.Type: GrantFiled: January 19, 2006Date of Patent: February 1, 2011Assignee: Alere InternationalInventors: Kenneth F. Buechler, Mariusz G. Banaszczyk, Joseph Barry Noar, Violeta Dinauer
-
Patent number: 7858658Abstract: Compounds of Formula (I), are provided where T is CHO, COR8, or C(OH)R1R2; R1 and R2 are hydrogen, optionally substituted lower alkyl, CF3, optionally substituted alkenyl, or optionally substituted alkynyl; R3 is hydrogen or optionally substituted lower alkyl; R4 is (CF3)nalkyl, (CF3)n(substitutedalkyl), (CF3)nalkylphenyl, (CF3)nalkyl(substitutedphenyl), or (F)ncycloalkyl; n=1-3; R5 is hydrogen, halogen, CF3, diene fused to Y when Y=C, or substituted diene fused to Y when Y=C; W, Y and Z are C, CR6 or N where at least one of W, Y or Z are C; R6 is hydrogen, halogen, or optionally substituted lower alkyl; X is O, S, SO2, or NR7; R7 is hydrogen, optionally substituted lower alkyl, optionally substituted benzyl, or optionally substituted phenyl; and R8 is lower alkyl, CF3, or optionally substituted phenyl. Methods of preparing and using these compounds for inhibiting beta amyloid production and for treatment of Alzheimer's Disease and Down's syndrome are also described.Type: GrantFiled: May 5, 2009Date of Patent: December 28, 2010Assignee: Wyeth LLCInventors: Anthony Frank Kreft, Lynn Resnick, Scott Christian Mayer, George Diamantidis, Derek Cecil Cole, Boyd Lynn Harrison, Minsheng Zhang, Molly Hoke, Tingzhong Wang, Rocco John Galante
-
Patent number: 7833693Abstract: The present application relates to a compound of formula A-X—B, where (i) A-X—B form an ionic compound Ai Xi Bi where Ai and Bi are each individually an organic onium cation; and Xi is anion of the formula Q-R500—SO3? or (ii) A-X—B form a non-ionic compound Ac-Xc-Bc, where Ai, Bi, Q, R500, Ac, Bc, and Xc are defined herein. The compounds are useful as photoactive materials.Type: GrantFiled: December 10, 2008Date of Patent: November 16, 2010Inventors: M. Dalil Rahman, Francis M. Houlihan, Munirathna Padmanaban, SangHo Lee, Ralph R. Dammel, David Rentkiewicz, Clement Anyadiegwu
-
3-Biphenyl-substituted-3-substituted-4-ketolactam and ketolactone and their utilization as pesticide
Publication number: 20100173778Abstract: The present invention relates to novel 3-biphenyl-substituted, 3-substituted 4-ketolactams and -lactones of the formula (I) in which A, B, Q, G, W, X, Y and Z are as defined in the disclosure, to processes for their preparation, and to their use as pesticides and/or microbicides and/or herbicides.Type: ApplicationFiled: October 23, 2007Publication date: July 8, 2010Inventors: Reiner Fischer, Astrid Ullmann, Thomas Bretschneider, Mark Wilhelm Drewes, Christoph Erdelen, Angelika Lubos-Erdelen, Dieter Feucht, Udo Reckmann, Karl-Heinz Kuck, Ulrike Wachendorff-Neumann -
Publication number: 20100120901Abstract: A pharmaceutical composition comprising a pharmaceutical diluent and a compound of formula IV wherein R21=H, C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, —CH2OR25, —C(O)R25, —CO(O)R25, —C(O)NR25R26, —CH2C(O)R25, or —CH2C(O)NHR25, where R25 and R26 are each independently H, C1-C10 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, optionally containing one or more halogen atoms. R22=—OH, —OR27, —OCH2C(O)R27, —OCH2C(O)NHR27, —OC(O)R27, —OC(O)OR27, —OC(O)NHNH—R5, or —OC(O)NR27R28, where R27 and R28 are each independently H, C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, and where R27 and R28 can each optionally contain halogen atoms; R23 and R24, the same or different from each other, are C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl. Methods of using such formulations for the treatment of cancer, to effect weight loss, to treat microbially-based infections, to inhibit neuropeptide-Y and/or fatty acid synthase, and to stimulate CPT-1.Type: ApplicationFiled: January 13, 2010Publication date: May 13, 2010Applicants: FASGEN,INC, THE JOHNS HOPKINS UNIVERSITYInventors: Francis P. Kuhajda, Susan M. Medghalchi, Jill M. McFadden, Jagan Thupari, Craig A. Townsend
-
Patent number: 7674397Abstract: The invention relates to new reactive mesogenic compounds with charge transport properties comprising at least two thiophene groups, their use as semiconductors or charge transport materials, in optical, electro-optical or electronic devices like for example liquid crystal displays, optical films, organic field effect transistors (FET or OFET) for thin film transistor liquid crystal displays and integrated circuit devices such as RFID tags, electroluminescent devices in flat panel displays, and in photovoltaic and sensor devices, and to a field effect transistor, light emitting device or ID tag comprising the reactive mesogenic charge transport compounds.Type: GrantFiled: February 25, 2005Date of Patent: March 9, 2010Assignee: Merck Patent Gesellschaff mit beschrankter HaftungInventors: Martin Heeney, Weimin Zhang, Steven Tierney, David Sparrowe, Maxim Shkunov, Iain McCulloch
-
Patent number: 7649012Abstract: A pharmaceutical composition comprising a pharmaceutical diluent and a compound of formula IV wherein R21=H, C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, —CH2OR25, —C(O)R25, —CO(O)R25, —C(O)NR25R26, —CH2C(O)R25, or —CH2C(O)NHR25, where R25 and R26 are each independently H, C1-C10 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, optionally containing one or more halogen atoms. R22=—OH, —OR27, —OCH2C(O)R27, —OCH2C(O)NHR27, —OC(O)R27, —OC(O)OR27, —OC(O)NHNH—R5, or —OC(O)NR27R28, where R27 and R28 are each independently H, C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, and where R27 and R28 can each optionally contain halogen atoms; R23 and R24, the same or different from each other, are C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl. Methods of using such formulations for the treatment of cancer, to effect weight loss, to treat microbially-based infections, to inhibit neuropeptide-Y and/or fatty acid synthase, and to stimulate CPT-1.Type: GrantFiled: July 9, 2003Date of Patent: January 19, 2010Assignees: FASgen, Inc., Johns Hopkins UniversityInventors: Francis P. Kuhajda, Susan M. Medghalchi, Jill M. McFadden, Jagan Thupari
-
Patent number: 7612108Abstract: The present invention relates to a 2-phenylthiophene derivative or a salt thereof, wherein the thiophene ring is substituted with a carboxyl group or the like and the benzene ring has an electron-withdrawing group such as a cyano group and an electron-donating group such as a substituted alkoxy group at the same time. Since the compound of the invention has good xanthine oxidase-inhibitory action and uric acid-lowering action and does not have a structure derived from nucleic acid, the compound has advantages of high safety and excellent effects as compared with conventional compounds and is useful as a therapeutic or preventive agent for hyperuricemia, gout, inflammatory bowel diseases, diabetic kidney diseases, diabetic retinopathy, or the like.Type: GrantFiled: August 26, 2005Date of Patent: November 3, 2009Assignee: Astellas Pharma Inc.Inventors: Junji Miyata, Masaki Yokota, Ryo Naito, Akio Kamikawa, Masakatsu Kawakami, Kazuyuki Hattori
-
Patent number: 7547725Abstract: Compounds of Formula (I), are provided where T is CHO, COR8, or C(OH)R1R2; R1 and R2 are hydrogen, optionally substituted lower alkyl, CF3, optionally substituted alkenyl, or optionally substituted alkynyl; R3 is hydrogen or optionally substituted lower alkyl; R4 is (CF3)nalkyl, (CF3)n(substituted alkyl), (CF3)nalkylphenyl, (CF3)nalkyl(substituted phenyl), or (F)ncycloalkyl; n=1-3; R5 is hydrogen, halogen, CF3, diene fused to Y when Y?C, or substituted diene fused to Y when Y?C; W, Y and Z are C, CR6 or N where at least one of W, Y or Z are C; R6 is hydrogen, halogen, or optionally substituted lower alkyl; X is O, S, SO2, or NR7; R7 is hydrogen, optionally substituted lower alkyl, optionally substituted benzyl, or optionally substituted phenyl; and R8 is lower alkyl, CF3, or optionally substituted phenyl. Methods of preparing and using these compounds for inhibiting beta amyloid production and for treatment of Alzheimer's Disease and Down's syndrome are also described.Type: GrantFiled: June 15, 2007Date of Patent: June 16, 2009Assignee: WyethInventors: Anthony Frank Kreft, Lynn Resnick, Scott Christian Mayer, George Diamantidis, Derek Cecil Cole, Boyd Lynn Harrison, Minsheng Zhang, Molly Hoke, Tingzhong Wang, Rocco John Galante
-
Patent number: 7541381Abstract: ?-lactamases are the most widespread resistance mechanism to ?-lactam antibiotics, such as penicillins and cephalosporins. In response to these enzymes, inhibitors have been introduced. Unfortunately, these inhibitors are also ?-lactams, and resistance to them has developed rapidly. Consequently, the present invention provides a novel structure-based approach to inhibitors of these enzymes.Type: GrantFiled: February 19, 2003Date of Patent: June 2, 2009Assignee: Northwestern UniversityInventors: Brian K. Shoichet, Rachael A. Powers
-
Patent number: 7541319Abstract: Fuels, especially hydrocarbon fuels, and lubricants, especially lubricating oils, contain a class of anti-corrosion, anti-wear, anti-fatigue, and extreme pressure additives that are derived from 1,3-dithiolane-2-thiones.Type: GrantFiled: June 27, 2005Date of Patent: June 2, 2009Assignee: Chemtura CorporationInventor: Robert G. Rowland
-
Patent number: 7521170Abstract: The present application relates to a compound of formula A-X—B, where (i)A-X—B form an ionic compound Ai Xi Bi where Ai and Bi are each individually an organic onium cation; and Xi is anion of the formula Q-R500—SO3? or (ii)A-X—B form a non-ionic compound Ac-Xc-Bc, where Ai, Bi, Q, R500, Ac, Bc, and Xc are defined herein. The compounds are useful as photoactive materials.Type: GrantFiled: February 16, 2006Date of Patent: April 21, 2009Assignee: AZ Electronic Materials USA Corp.Inventors: M. Dalil Rahman, Francis M. Houlihan, Munirathna Padmanaban, SangHo Lee, Ralph R. Dammel, David Rentkiewicz, Clement Anyadiegwu
-
Patent number: 7507817Abstract: Novel compounds, and therapeutic methods, compositions and medicament related thereto are disclosed herein.Type: GrantFiled: November 13, 2007Date of Patent: March 24, 2009Assignee: Allergan, Inc.Inventors: David W. Old, Vinh X. Ngo, Wha-Bin Im
-
Publication number: 20090048455Abstract: The present invention relates to a process for the manufacture of cyclic thio esters (thiolactones) and related compounds by hydrogenation of cyclic thioanhydrides in the presence of metal catalysts.Type: ApplicationFiled: April 12, 2006Publication date: February 19, 2009Inventors: Werner Bonrath, Reinhard Karge, Felix Roessler
-
Patent number: 7482376Abstract: The present invention is directed to conjugated complement cascade inhibitors, and a method of treating a patient using a conjugated complement cascade inhibitor.Type: GrantFiled: June 16, 2004Date of Patent: January 27, 2009Assignee: 3-Dimensional Pharmaceuticals, Inc.Inventors: Nalin Subasinghe, Ehab Khalil, Farah Ali, Heather Rae Hufnagel, Shelley Ballentine, Jeremy M. Travins, Kristi A. Leonard, Roger F. Bone
-
Publication number: 20090005435Abstract: A pharmaceutical composition comprising a pharmaceutical diluent and a compound of formula (II), wherein R1 and R2, the same or different from each other, are H, C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, —CH2CORS, —CH2C(O)NRS, —C(O)R5, or —CH2OR5, and can optionally contain halogen atoms, where R5 is a C1-C12 alkyl group. R3 and R4, the same or different from each other, are H, C1-C20 alkyl cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.Type: ApplicationFiled: May 25, 2005Publication date: January 1, 2009Inventors: Jill M. Sturdivant, Craig Townsend, Susan Medghalchi
-
Patent number: 7432381Abstract: The present invention relates to 1,3-oxathiolane-2-thione compounds of the general formula (I): wherein R1 and R2 are the same or different, each of which denotes a straight-chain or branched alkoxy residue with 1 to 6 carbon atoms or an aryloxy or aralkyloxy residue, R3 is different or the same as R1 or R2 or an aliphatic residue, an amino residue, a halogen residue, an aromatic or heteroaromatic residue, or an araliphatic or heteroaraliphatic residue, R4 is a bridging group selected from the groups consisting of aliphatic, heteroaliphatic, araliphatic, heteroaraliphatic, aromatic and heteroaromatic groups and R5 is hydrogen, an aliphatic, heteroaliphatic, araliphatic, heteroaraliphatic, aromatic, heteroaromatic, cycloaliphatic or heterocycloaliphatic group or R4 and R5 form a cycloaliphatic, cycloheteroaliphatic, aromatic or heteroaromatic residue, which is optionally substituted with an aliphatic, heteroaliphatic residue serving as a bridging group to the silicon atom and X and Y are different and seleType: GrantFiled: February 15, 2006Date of Patent: October 7, 2008Assignee: Henkel Kommanditgesellschaft auf AktienInventors: Kazuya Uenishi, Atsushi Sudo, Hiroshi Morikawa, Takeshi Endo, Olaf Lammerschop, Thomas Huver, Pavel Gentschev
-
Patent number: 7423170Abstract: Oncoproteins such as Ras and RhoB are known to induce cell division in an unrestrained manner when such proteins are localized at the inner surface of a cancer cell membrane. The localization is effected by the prenylation reaction, whereby a hydrophobic group (e.g. a farnesyl group) is attached to the protein in the presence of an enzyme (e.g. farnesyl protein transferase). Deactivation of the prenylation enzyme through covalent modification can therefore ultimately result in the mitigation and/or cessation of cancer cell growth. Various prenylation inhibitors having the necessary structural groups to bond covalently, or essentially irreversibly, to the prenylation enzyme include carbonyl or thiocarbonyl compounds (or masked versions of these compounds) and alpha oxo-epoxides bonded to a hydrophobic, substrate-mimicking group. The carbonyl or thiocarbonyl compounds also contain a nucleofugal atom or group to enhance the tendency to form covalent bonds.Type: GrantFiled: January 23, 2006Date of Patent: September 9, 2008Assignee: Arizona Biomedical Research CommissionInventors: Seth D. Rose, Scott R. Lefler, Steven R. Ottersberg, Ann Y. Kim, Karl J. Okolotowicz, Rosemarie F. Hartman
-
Patent number: 7390613Abstract: The present application relates to a compound of formula Ai Xi Bi where Ai and Bi are each individually an organic onium cation; and Xi is anion of the formula ?O3S—CF2CF2OCF2CF2—SO3?. The compounds are useful as photoactive materials.Type: GrantFiled: December 4, 2006Date of Patent: June 24, 2008Assignee: AZ Electronic Materials USA Corp.Inventors: M. Dalil Rahman, David L. Rentkiewicz
-
Patent number: 7351841Abstract: A compound represented by the formula (1): wherein A is a nitrogen atom or CR4, B is an oxygen atom, a sulfur atom or NR9 (provided that when A is a nitrogen atom, B is not NH), R1 is a C2-14 aryl group, L1 is a bond, CR10R11, an oxygen atom, a sulfur atom or NR12, X is OR13 SR13 or NR14NR15, R2 is a hydrogen atom, a formyl group, a C1-10 alkyl group or the like, L2 is a bond or the like, L3 is a bond, CR17R18, an oxygen atom, a sulfur atom or NR19, L4 is a bond, CR20R21, an oxygen atom, a sulfur atom or NR22, Y is an oxygen atom, a sulfur atom or NR23, and R3 is a C2-14 aryl group, a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.Type: GrantFiled: December 6, 2005Date of Patent: April 1, 2008Assignee: Nissan Chemical Industries, Ltd.Inventors: Shingo Owada, Shunsuke Iwamoto, Kazufumi Yanagihara, Katsuaki Miyaji, Takanori Nakamura, Norihisa Ishiwata, Yutaka Hirokawa
-
Publication number: 20080050787Abstract: A method for manufacturing (R)-tetrahydrothiophene-3-ol denoted by formula (II): by bioconversion of tetrahydrothiophene-3-one denoted by formula (I): to (R)-tetrahydrothiophene-3-ol denoted by formula (II). It comprises the steps of: (A) incubating the tetrahydrothiophene-3-one denoted by formula (I) in the presence of a strain, or a preparation of a cultured cell thereof, belonging to Penicillium, Aspergillus, or Streptomyces that is capable of said bioconversion; and (B) collecting the (R)-tetrahydrothiophene-3-ol denoted by formula (II) from incubated solution. A method for crystallization of optically active tetrahydrothiophene-3-ol of improved optical purity, characterized by maintaining a solution comprising optically active tetrahydrothiophene-3-ol and organic solvent at equal to or lower than 1° C.Type: ApplicationFiled: December 1, 2004Publication date: February 28, 2008Inventors: Hazuki Nagai, Kaname Konuki, Masashi Ito, Tomohiro Sameshima
-
Patent number: 7300951Abstract: Compounds of Formula (I), are provided where T is CHO, CON, or C(OH)R1R2; R1 and R2 are hydrogen, optionally substituted lower alkyl, CF3, optionally substituted alkenyl, or optionally substituted alkynyl; R3 is hydrogen or optionally substituted lower alkyl; R4 is (CF3)nalkyl, (CF3)n(substitutedalkyl), (CF3)nalkylphenyl, (CF3)nalkyl(substitutedphenyl), or (F)ncycloalkyl; n=1-3; R5 is hydrogen, halogen, CF3, diene fused to Y when Y?C, or substituted diene fused to Y when Y?C; W, Y and Z are C, CR6 or N where at least one of W, Y or Z are C; R6 is hydrogen, halogen, or optionally substituted lower alkyl; X is O, S, SO2, or NR7; R7 is hydrogen, optionally substituted lower alkyl, optionally substituted benzyl, or optionally substituted phenyl; and R8 is lower alkyl, CF3, or optionally substituted phenyl. Methods of preparing and using these compounds for inhibiting beta amyloid production and for treatment of Alzheimer's Disease and Down's syndrome are also described.Type: GrantFiled: March 26, 2004Date of Patent: November 27, 2007Assignee: WyethInventors: Anthony Frank Kreft, Lynn Resnick, Scott Christian Mayer, George Diamantidis, Derek Cecil Cole, Boyd Lynn Harrison, Minsheng Zhang, Molly Hoke, Tingzhong Wang, Rocco John Galante
-
Publication number: 20070213524Abstract: Heterocycles, e.g., epoxides, are carbonylated at low pressure with high percentage conversion to cyclic, ring expanded products using the catalyst where L is tetrahydrofuran (THF).Type: ApplicationFiled: February 13, 2007Publication date: September 13, 2007Applicant: Cornell Research Foundation, Inc.Inventors: Geoffrey W. Coates, John Kramer
-
Patent number: 7262310Abstract: A process for preparing 3-hydroxythiolane which is characterized in reacting a compound of the following formula, wherein X is halogen atom, and R2 is substituted or unsubstituted alkyl group, substituted or unsubstituted aralkyl group, or substituted or unsubstituted aryl group, with a metal sulfide.Type: GrantFiled: March 29, 2005Date of Patent: August 28, 2007Assignee: Daiso Co., Ltd.Inventors: Kazumasa Hinoue, Masafumi Mikami
-
Publication number: 20070197800Abstract: Processes for preparing sulfonamide trifluoroalkyl substituted alcohol compounds are provided. Desirably, the compounds are heterocyclic sulfonamide trifluoroalkyl substituted alcohol compounds or phenyl sulfonamide trifluoroalkyl substituted alcohol compounds.Type: ApplicationFiled: February 15, 2007Publication date: August 23, 2007Applicant: WyethInventors: Anita Wai-Yin Chan, Jianxin Ren, Mousumi Ghosh, Panolil Raveendranath